IN8bio, Inc. INAB
0.78 USD -0.04 (-4.88%)
Regular-session close
0.77 -0.01 -1.64%
After hours · Nov 18, 4:00 PM ET
0.76 Day range 0.82
0.78 52-week range 2.59
- YTD
- -66.67%
- 1 year
- -52.44%
News
benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session Gainers Dare Bioscience (NASDAQ:DARE) shares rose 9.5% to $0.64 during Monday's after-market session. The company's market cap stands at $12.9 million. As per the press release, Q3 earnings came out…benzinga.com IN8bio Presents Updated Clinical Data From INB-200 And INB-400 Programs In Newly Diagnosed GBM, In Oral Session At 2026 SNO Annual Meeting Median overall survival (mOS) of 20.9 months in repeat-dose patients, compared to 13.2 months (+59%) in the group receiving standard-of-care (SOC)50% of repeat-dose patients remained alive at two…
globenewswire.com IN8bio Reports Updated Glioblastoma Data at SNO 2026 Demonstrating Median Overall Survival of 20.9 Months and 50% Two-Year Survival with Gamma-Delta T Cell Therapy IN8bio Reports Updated Glioblastoma Data at SNO 2026 Demonstrating Median Overall Survival of 20.9 Months and 50% Two-Year Survival with Gamma-Delta T Cell
globenewswire.com IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) NEW YORK, Nov. 06, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (the “Company”) (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies and T cell…
globenewswire.com IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) NEW YORK, Oct. 06, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (the “Company”) (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies and T cell…
defenseworld.net IN8bio Highlights Glioblastoma Survival Data, Eyes Autoimmune T-Cell Engager Milestone IN8bio (NASDAQ: INAB) outlined updates across its gamma-delta T-cell programs in autoimmune disease and oncology, including preclinical plans for its T-cell engager platform and clinical data in…
globenewswire.com IN8bio to Present at Sidoti Small-Cap Virtual Conference NEW YORK, Sept. 22, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies and T cell engagers for…
globenewswire.com IN8bio to Present at H.C. Wainwright 28th Annual Global Investment Conference NEW YORK, Sept. 10, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies and T cell engagers for…
globenewswire.com IN8bio Appoints Oxana Polyakova, Ph.D., as Senior Vice President of Research & Development Renowned γδ T cell and T cell engager (TCE) expert brings two decades of drug discovery and development experience to IN8bio Appointment strengthens IN8bio's leadership and domain expertise as they…
globenewswire.com IN8bio Announces Publication in The Journal of Clinical Oncology Demonstrating DeltEx™ DRI Doubles Progression-Free Survival in Newly Diagnosed Glioblastoma First peer-reviewed publication of chemotherapy-resistant gamma-delta T cells (DeltEx Drug Resistant Immunotherapy or DRI) clinical results in newly diagnosed glioblastoma Repeat-dose patients…
zacks.com IN8bio (INAB) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now After losing some value lately, a hammer chart pattern has been formed for IN8bio (INAB), indicating that the stock has found support. This, combined with an upward trend in earnings estimate…
globenewswire.com IN8bio Announces Publication in Nature Communications Highlighting Advances in Gamma-Delta T Cell Engineering and Combination Therapies NEW YORK, June 03, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (NASDAQ: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies and T cell engagers (TCEs)…
globenewswire.com IN8bio Presents Updated Overall Survival Data Surpassing 19.5 Months for DeltEx DRI in Newly Diagnosed Glioblastoma at ASCO 2026 Repeat dosing of DeltEx TM Drug Resistant Immunotherapy (DRI) had a median progression-free survival (mPFS) of 13.0 months and median overall survival (mOS) exceeding 19.5 months (not yet reached).…
globenewswire.com IN8bio Reports First Quarter 2026 Financial Results and Recent Business Highlights Advancing next-generation γδ T cell engager platform with initial animal data expected in 2026 Reported glioblastoma (GBM) data showing ~97% improvement in progression-free survival vs.…
globenewswire.com IN8bio to Showcase Next-Generation T Cell Engager Platform and New Clinical Data at Upcoming R&D Day and Medical Conferences NEW YORK, May 06, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB) (“IN8bio” or the “Company”), a clinical-stage biopharmaceutical company developing innovative gamma-delta (“γδ”) T cell…
globenewswire.com IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) NEW YORK, April 03, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (the “Company”) (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative γδ T cell therapies for cancer and…
defenseworld.net Comparing XBiotech (NASDAQ:XBIT) & IN8bio (NASDAQ:INAB) IN8bio (NASDAQ: INAB - Get Free Report) and XBiotech (NASDAQ: XBIT - Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two businesses…
globenewswire.com IN8bio Reports Fourth Quarter and Full-Year 2025 Financial Results - Highlights Durable Survival Improvements in Glioblastoma, Advancing Pipeline and Strengthened Financial Position for 2026 Presented updated glioblastoma (“GBM”) data demonstrating durable survival and a favorable safety profile across Phase 1 and Phase 2 programs, with repeat dosing of DeltEx™ Drug-Resistant…
globenewswire.com IN8bio to Present at TD Cowen 46th Annual Health Care Conference NEW YORK, Feb. 24, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies for cancer and autoimmune…
globenewswire.com IN8bio Promotes Kate Rochlin, Ph.D., to President and Chief Operating Officer NEW YORK, Feb. 09, 2026 (GLOBE NEWSWIRE) -- IN8bio (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ ) T cell therapies and T cell engagers for cancer…
globenewswire.com IN8bio to Present at Upcoming Investor and Scientific Conferences in February NEW YORK, Feb. 03, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ ) T cell therapies for cancer and autoimmune…
globenewswire.com IN8bio Presents Updated Phase I/II Data Demonstrating Meaningful and Durable Survival Improvements in Newly Diagnosed Glioblastoma NEW YORK, Jan. 12, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ ) T cell therapies for cancer and autoimmune…
